
Annual Shareholders' Meeting 2014

20 August 2014



Tony Carter - Chairman





Your Board



Tony Carter



Michael Daniell



Roger France



Lindsay Gillanders



Geraldine McBride



Arthur Morris



Donal O'Dwyer



Agenda

CHAIR'S ADDRESS

MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER'S REVIEW

FINANCIAL STATEMENTS

RESOLUTIONS

VOTING

GENERAL QUESTIONS



Our Business

9_{million+}

PATIENTS TREATED DURING THE YEAR USING OUR MEDICAL DEVICES

123

COUNTRIES WHERE OUR PRODUCTS WERE SOLD DURING THE YEAR

Z, O O O +

34

COUNTRIES WHERE
OUR PEOPLE ARE LOCATED


200+

DISTRIBUTORS WORLDWIDE

US\$5billion+

2.700+


TOTAL RANGE OF PRODUCTS, ACCESSORIES AND PARTS





Our Opportunity

Healthcare costs are increasing at a rapid rate.



 The sector is looking for new and better ways to deliver efficient and effective solutions – Fisher & Paykel Healthcare is well positioned to meet this need.

Fisher & Paykel

2014 Financial Snapshot

NZ\$ **97.1** m

RECORD NET PROFIT AFTER TAX

26%

GROWTH IN NET PROFIT AFTER TAX

NZ\$ **623.4**m

RECORD OPERATING REVENUE

12.4cps


TOTAL DIVIDEND FOR THE YEAR FULLY IMPUTED



Dividend

 We are approaching our target level of gearing

 The Board will give consideration to increasing the dividend this financial year



Gearing ratios have been calculated/forecast at 31 March of each financial year.

^{1.} Net interest-bearing debt (debt less cash and cash equivalents) to net interest-bearing debt and equity (less cash flow hedge reserve - unrealised)



Our Team





Your Board



Tony Carter



Michael Daniell



Roger France



Lindsay Gillanders



Geraldine McBride




Arthur Morris



Donal O'Dwyer



Tony Carter - Chairman





Michael Daniell - Managing Director & Chief Executive Officer



Continuous Product Improvement



Serving More Patients & More Products for Each Patient







Noninvasive Ventilation









Invasive Ventilation Neonatal



T-Piece Resuscitation



Optiflow Junior



CPAP Therapy



Increase our international presence

5%

REVENUE BY REGION 12 MONTHS TO 31 MARCH 2014 NORTH AMERICA 42% EUROPE 34% ASIA-PACIFIC 19%

OTHER





A Proven Strategy



Continuous product improvement



Serve more patient groups



More products for each patient




Increase our international presence




2014 Financial Highlights

	12 Months Ended 31 March 2013 (NZ\$m)	12 Months Ended 31 March 2014 (NZ\$m)	% Change
Operating revenue	556.3	623.4	+12%
RAC operating revenue	301.5	336.9	+12%
OSA operating revenue	235.8	270.0	+15%
Net profit after tax	77.1	97.1	+26%


Constant currency growth





Fisher & Paykel


Respiratory and Acute Care (RAC)



Breathing device to be trialled in Africa



Obstructive Sleep Apnea (OSA)





Graham Lowe on OSA



Obstructive Sleep Apnea (OSA)





Outlook

First Half	
Operating Revenue	~NZ\$315 million
Net Profit after Tax	~NZ\$45 million

Full Year

Expect at NZD:USD exchange rate of ~0.84 for the balance of the year

Operating Revenue ~NZ\$650 million

Net Profit after Tax ~NZ\$100 million




Michael Daniell - Managing Director & Chief Executive Officer



Financial Statements

- Opportunity for shareholders to ask any questions specifically on the financial statements, the auditors' report or the company's 2014 annual report.
- There will be an opportunity to ask any general questions once all items on the agenda have been considered.





Resolutions

Re-election of Directors

Auditor's Remuneration

Directors' Remuneration

- Issue of Performance Share Rights
- Issue of Options



Voting

 In respect of each resolution, please tick the "for", "against" or "abstain" box.

 Once you have completed your voting, please place your vote in a ballot box.

- Please raise your hand if you require a pen.
- Results will be announced to NZX and ASX as soon as they are available.



Q&A





Annual Shareholders' Meeting 2014

20 August 2014

